QSI Straight to $2.84-$3.08 Targets Premium BUYS $1.16-$1.23 Premium SELLS $2.84-$3.08 TP 1 $2.84 TP 2 $3.00 TP 3 $3.08 TP 4 $3.20 All of these targets will be reached before ending of January 2025Longby lifeonedge779
QSI on track for 2.93 resistance, Anything Under $1.20 is goldenQSI in an an ascending triangle breakout if we break past $1.61 we are headed for straight above $2-3. Quantum stocks to the moon. Longby tg4e7714
Quantum-Si Inc - Awaiting bullish momentum to break the necklineInverse head and shoulders spotted on the daily time frame. Currently retesting the neckline @ $1.85. Waiting for bullish momentum/volume to enter this trade. Price is currently below the 50 SMA. Take profit: $3.92 Stop loss: $1.70 Longby Trey0214
Quantum-Si, biotech stock near pivotQuantum-Si NASDAQ:QSI , develops access to the proteome with single-molecule analysis and democratizing to researchers & clinicians Also, "is the world’s first-to-market provider of protein sequencing instruments with core technology based on proprietary time-domain sequencing that enables resolution of amino acids during experiments".- Ark Invest The stock is near finalizing its bottoming process with a pivot buy at $2.50 The Biotech ETF AMEX:XBI already broke out so NASDAQ:QSI is no leader, but still is a good set up.Longby dpuleo190
QSI Quantum-Si incorporated Potential ReentryIf you haven`t bought the Double Bottom on QSI: Then it seems that there is a potential reversal from this level. Earnings were a beat, but too small to justify the recent breakout. The Elliot Waves chart pattern indicates a price target of $2.93. Looking forward to read your opinion about it! Longby TopgOptions112
QSI Quantum-Si Earnings Release on Monday, Before the BellIf you haven`t bought the Double Bottom: Then you should know that QSI, Quantum-Si incorporated, also known as The Protein Sequencing Company is bringing single-molecule protein sequencing to every lab, everywhere, enabling new discoveries that will transform the world we live in. Importance of Protein Sequencing: - Understanding Cellular Processes: Proteins are involved in virtually every cellular process, and their sequencing is vital for understanding how these processes are regulated and how dysfunction leads to diseases. - Drug Development: Protein sequencing assists in drug discovery by identifying specific targets for pharmaceutical intervention. This knowledge enables the design of drugs that can interact with specific proteins, thereby treating diseases more effectively. - Bioengineering and Enzyme Production: Protein sequencing is critical in the field of bioengineering, allowing the design of proteins with tailored functions for various applications, including industrial enzyme production and bioremediation. I think protein sequencing should have the same importance as gene sequencing. Gene sequencing has revolutionized medical research, agriculture, and our comprehension of evolutionary history. On the other hand, protein sequencing has paved the way for targeted drug development, bioengineering, and the investigation of cellular processes. QSI has cash and cash equivalents of $322.1 million as of March 31,2023 to provide a runway to support operations and invest in the business into 2026, and NO debt! This Quarter started he sale of PlatinumTM instruments and kits with a gross margin of 48.8%. QSI has a Market Cap of $485Mil vs CRSP, my favorite gene editing company, with a Market Cap of 4.046Bil. So there is still a lot of upside in QSI Quantum-Si incorporated! Looking forward to read your opinion about it. Longby TopgOptions4
QSI Quantum-Si | Why is so Bullish? Price Target ! If you haven`t bought the Double Bottom here: Then I'll try an explanation why QSI Quantum-Si incorporated is so Bullish right now! QSI is a protein sequencing company, which could be revolutionary, similar to the gene sequencing stocks. Quantum-Si Incorporated is dedicated to developing a protein detection platform that enables Next Generation Protein Sequencing (NGPS). This comprehensive platform consists of the Carbon automated sample preparation instrument, the Platinum single-molecule detection and NGPS instrument with Time-Domain Sequencing chip, the Quantum-Si Cloud data analysis software, and reagent kits designed for use with its instruments. QSI's competitor, RXRX, experienced a significant boost in its stock price after announcing a $50 million investment from NVIDIA (NASDAQ: NVDA) on July 12. The investment was part of a private investment in public equity (PIPE) arrangement. With this deal, NVIDIA gains access to Recursion Pharmaceuticals' (NASDAQ: RXRX) extensive biochemical and genetic data. NVIDIA plans to utilize this data to train machine-learning models in support of its new BioNeMo service, an artificial intelligence (AI) tool for drug discovery. Simultaneously, NVIDIA will also collaborate with Recursion to enhance their own models for drug discovery. Apart from Quantum-Si's Platinum product, which began selling this quarter, the company also offers cloud-based proteomics data analysis software, made possible by their single-molecule detection and NGPS instrument with Time-Domain Sequencing chip. Considering this, I believe it's only a matter of time until a major chip developer, such as NVDA, or a cloud services company with interest in the field, makes an investment similar to NVDA's investment in RXRX. This is my growth thesis, and regarding the Price Target, I find $10 to be reasonable for now, and there's also the possibility of a potential buyout. Looking forward to read your opinion about it!Longby TopgOptions443
QSI Bullish Divergence in play!Hi Folks! The bulk of my idea is noted on the chart. I want to also note that volume has cooled down from the 10 day avg during this consolidation. I'll watch to see if it increases to prepare for a move to the upside. I hope this helps anyone and thank you for your time! Happy Trading! OnePathby OnePath2
QSI Growth Thesis ! ARK Biggest Shareholder Accumulating !Quantum-Si (QSI), currently trading at $1.55, presents an intriguing growth opportunity with the potential to at least double in value. Several factors contribute to this growth thesis: Disruptive Technology: QSI's technology has the capability to revolutionize the discovery of new diagnostic tests and pharmaceuticals through digitization. By leveraging AI and digitizing the industry, QSI can significantly accelerate and reduce the cost of these discoveries. The implementation of AI has the potential to exponentially enhance the speed and efficiency of the process, positioning QSI at the forefront of innovation in the field. Founder's Confidence: Jonathan Rothberg, the founder of QSI, has displayed unwavering confidence in the company's future. Notably, Rothberg has not sold a single share and, in fact, acquired tens of thousands of shares in the $3-4 range last year. This demonstrates his belief in the company's long-term potential, which is a rarity among new companies. In contrast to many other recent IPOs, where founders and CEOs have been selling shares, Rothberg's continued investment reflects his dedication and commitment to QSI's success. Strong Financial Position: QSI boasts a robust financial position with over $330 million in cash and zero debt. This substantial cash reserve provides the company with a secure foundation and ample resources to fund operations for at least three years. This financial stability is uncommon for a company that went public through a SPAC, instilling confidence in QSI's ability to execute its plans without facing immediate financial constraints. Strengthening Executive Team: QSI has been bolstering its executive team, attracting talented individuals from reputable companies such as ILMN (Illumina). This strategic move enhances QSI's expertise and further positions the company for successful execution of its plans. The addition of experienced professionals from a prominent industry player underscores QSI's commitment to assembling a capable team to drive growth and innovation. ARK's Support: ARK, an influential investment firm, has been actively accumulating QSI shares, driving up demand and limiting the availability of public shares. With approximately 9.75% ownership in QSI and an average acquisition price of $9.91, ARK's confidence in the company's potential is evident. Their continued investments, as seen in their recent purchase worth $675K, signal a positive outlook for QSI and attract attention from other investors. From a technical analysis perspective, Quantum-Si (QSI) appears to be forming a double bottom pattern, which can indicate a potential trend reversal and a bullish signal. The double bottom pattern is characterized by two distinct price lows, with a moderate upward price movement in between, forming a "W" shape on the chart. In the case of QSI, the formation of a double bottom pattern suggests that selling pressure may be diminishing, and buyers could potentially step in to drive the stock's price higher. This pattern often signifies a shift in market sentiment from bearish to bullish. Based on the double bottom pattern, some technical analysts may project a potential price target. In this case, the price target of $1.93 indicates the expected upside move if QSI breaks above the pattern's neckline or resistance level. Considering these factors, Quantum-Si (QSI) presents an intriguing growth opportunity. The disruptive technology, founder's confidence, strong financial position, strengthened executive team, and support from influential investors contribute to a compelling investment thesis. While investments involve risks, QSI's current valuation of $1.55 potentially offers significant upside, with the potential for at least doubling in value based on the provided information. Looking forward to read your opinion about it!Longby TopgOptionsUpdated 111112
QSI Quantum-Si Incorporated Double BottomQSI started the reversal I was mentioning here: Quantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. QSI is heading to the next resistance, $2.52, which I think is the price target of this stock for now. Cathie Wood`s ARK Invest is the biggest shareholder with an Estimated Average Price Paid of $9.91/share. So I`m extremely optimistic about the future of this company. Looking forward to read your opinion about it. Longby TopgOptionsUpdated 2
$QSIAlong a final line of support @ $7.85. Triple classic bullish divergence on the daily MACD and classic bullish divergence on the daily RSI too. Should get a nice bounce but will keep an eye out for more of a reversal too. Stop = Candle close below supportLongby Joshh_Tradess1
QSI looks bullishIt seems that not only Kathy Wood was buying QSI last times. It looks like other big guys are also quietly buying and not selling. Holds the support level well. Made cup and handle (or Vbottom, right extention) pattern on the hourly timeframe. Watching this closely for a long swing.Longby AnaBloemkool553